Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer

doi:10.3748/wjg.117832

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 29

This Article

(19)

(22)

(0)

(1)

(776)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Aug 7, 2026; 32(29): 117832
Published online Aug 7, 2026. doi: 10.3748/wjg.117832

Full Size Figure Download Figure

Figure 2 Kaplan-Meier estimates of overall survival from the start of magnetic resonance-guided radiotherapy, Eastern Cooperative Oncology Group performance status, baseline carbohydrate antigen 19-9 level at the beginning of magnetic resonance-guided radiotherapy, and radiographic response of distant metastases to chemotherapy. A: Stratified by solitary-organ metastases vs multiple-organ metastases; B: Eastern Cooperative Oncology Group performance status (0 vs 1-2); C: Baseline carbohydrate antigen 19-9 level at the beginning of magnetic resonance-guided radiotherapy (< 500 U/mL vs > 500 U/mL); D: Radiographic response of distant metastases to chemotherapy (stable vs uncontrolled). mOS: Median overall survival; ECOG: Eastern Cooperative Oncology Group; CA19-9: Carbohydrate antigen 19-9; RT: Radiotherapy.

Citation: Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832
URL: https://www.wjgnet.com/1007-9327/full/v32/i29/117832.htm
DOI: https://dx.doi.org/10.3748/wjg.117832

Schumann MA, Gaasch A, Boyaci S, Fuchs F, Walter F, Marschner SN, Eze C, Westphalen CB, Holch JW, Beyer G, Kunz WG, Mayerle J, Niyazi M, Belka C, Corradini S, Rogowski P. Five-fraction stereotactic magnetic resonance-guided adaptive radiotherapy targeting the primary tumor in metastatic pancreatic cancer. World J Gastroenterol 2026; 32(29): 117832 [DOI: 10.3748/wjg.117832]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.